Cosmos Health INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Cosmos Health Inc. reported increased revenue for the six months ended June 30, 2026, but also a significant net loss and substantial doubt about its ability to continue as a going concern.
NASDAQ
Cosmos Health Inc. reported a significant increase in revenue for Q3 and the nine months ended September 30, 2025, driven by strategic expansions and acquisitions, though net losses widened due to substantial non-cash charges and increased financing costs.
NASDAQ
Cosmos Health Inc. reported increased revenue and gross profit for Q2 2025, alongside a reduced net loss, but acknowledged persistent substantial doubt about its ability to continue as a going concern despite securing a new $300 million convertible note facility.
NASDAQ
Cosmos Health Inc.'s Q1 2025 results show a slight revenue decrease but a significant reduction in net loss, driven by a shift towards higher-margin product lines and cost management efforts.
NASDAQ
Cosmos Health Inc. reported its third quarter 2024 results, showing a slight decrease in revenue compared to the same period last year, while also expressing substantial doubt about its ability to continue as a going concern.
NASDAQ
Cosmos Health Inc. reports a 12.45% increase in revenue year-over-year for the six months ended June 30, 2024, while also noting a net loss of $4.45 million.
NASDAQ
10-Q: Cosmos Health Inc. Reports First Quarter 2024 Results with Revenue Growth but Increased Net Loss
Cosmos Health Inc. saw a revenue increase in the first quarter of 2024, but also experienced a larger net loss compared to the same period last year.